{"id":82893,"date":"2020-03-31T15:27:33","date_gmt":"2020-03-31T18:27:33","guid":{"rendered":"https:\/\/megalabs.global\/eng\/?p=82893"},"modified":"2020-04-13T19:01:13","modified_gmt":"2020-04-13T22:01:13","slug":"francia-aprueba-el-empleo-de-cloroquina-en-covid-19","status":"publish","type":"post","link":"https:\/\/megalabs.global\/eng\/francia-aprueba-el-empleo-de-cloroquina-en-covid-19\/","title":{"rendered":"Francia aprueba el empleo de cloroquina en COVID-19"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”100″ gutter_size=”3″ shift_y=”0″ row_height_use_pixel=””][vc_column column_width_use_pixel=”yes” gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ medium_width=”0″ zoom_width=”0″ zoom_height=”0″ column_width_pixel=”800″][vc_column_text]El ministro de salud de Francia Olivier V\u00e9ran ha publicado este jueves un decreto en el diario oficial de Francia.<\/strong><\/p>\n

Vinculo a la noticia<\/a><\/p>\n

A todos los fines (regulatorios, informativos, etc.) el decreto es \u00fanico y se encuentra aqu\u00ed:<\/p>\n

Vinculo al decreto<\/a><\/p>\n

Tambi\u00e9n lo adjuntamos al presente correo. La aprobaci\u00f3n se produce por decreto y no por decisi\u00f3n de la ANSM.<\/p>\n

El decreto dispone que [\u2026] hidroxicloroquina y lopinavir \/ ritonavir se puede recetar, dispensar y administrar bajo la responsabilidad de un m\u00e9dico a pacientes afectados por covid-19, en los establecimientos de atenci\u00f3n m\u00e9dica que los apoyan, as\u00ed como a continuaci\u00f3n de su tratamiento si su condici\u00f3n lo permite y con la autorizaci\u00f3n del prescriptor inicial, en el hogar.<\/p>\n

El producto se comercializa comprimidos. Sin embargo, la Sociedad Espa\u00f1ola de Farmacia Hospitalaria posee un protocolo para moler los comprimidos y administrarlos por sonda. El mismo est\u00e1 disponible en:<\/p>\n

Vinculo al protocolo<\/a><\/p>\n

Foto bajo licencia Creative Commnos por Yeray David Rodr\u00edguez – Flickr[\/vc_column_text][\/vc_column][\/vc_row][vc_row unlock_row=”” row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”100″ gutter_size=”3″ column_width_use_pixel=”yes” shift_y=”0″ z_index=”0″ row_height_use_pixel=”” column_width_pixel=”800″][vc_column width=”1\/1″][vc_row_inner row_inner_height_percent=”0″ overlay_alpha=”50″ gutter_size=”3″ border_color=”color-877404″ border_style=”solid” shift_y=”0″ z_index=”0″ css=”.vc_custom_1572995729128{border-top-width: 1px !important;border-bottom-width: 1px !important;padding-top: 18px !important;padding-bottom: 18px !important;}” el_class=”descarga-pdf” limit_content=””][vc_column_inner width=”1\/1″][vc_icon position=”left” icon_image=”82110″ icon_color=”color-877404″ media_size=”42″ text_font=”font-195522″ text_weight=”700″ linked_title=”yes” title=”Descargar Documento” link=”url:%2Fwp-content%2Fuploads%2F2020%2F03%2FDecreto-del-Gobierno-de-Francia-Cloroquina-en-COVID-19.pdf||target:%20_blank|”]Decreto del Gobierno de Francia Cloroquina en COVID-19<\/p>\n

 <\/p>\n

 <\/p>\n

[\/vc_icon][vc_icon position=”left” icon_image=”82110″ icon_color=”color-877404″ media_size=”42″ text_font=”font-195522″ text_weight=”700″ linked_title=”yes” title=”Descargar Documento” link=”url:%2Fwp-content%2Fuploads%2F2020%2F03%2FConclusi%C3%B3n-uso-hQ-en-COVID-19.pdf||target:%20_blank|”]Conclusi\u00f3n uso hQ en COVID-19<\/p>\n

 <\/p>\n

 <\/p>\n

[\/vc_icon][vc_icon position=”left” icon_image=”82110″ icon_color=”color-877404″ media_size=”42″ text_font=”font-195522″ text_weight=”700″ linked_title=”yes” title=”Descargar Documento” link=”url:%2Fwp-content%2Fuploads%2F2020%2F03%2FHIDROXICLOROQUINA_SULFATO_25mg_ml_SUSP_PNT.pdf||target:%20_blank|”]Hidroxicloroquina<\/p>\n

 <\/p>\n

 <\/p>\n

[\/vc_icon][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

El ministro de salud de Francia, Olivier V\u00e9ran, ha publicado este jueves un decreto en el diario oficial de Francia habilitando su uso.<\/p>\n","protected":false},"author":1,"featured_media":82925,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[99],"tags":[],"class_list":["post-82893","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias-cm"],"_links":{"self":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/82893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/comments?post=82893"}],"version-history":[{"count":0,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/82893\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media\/82925"}],"wp:attachment":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media?parent=82893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/categories?post=82893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/tags?post=82893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}